EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants

Sarah C J Jorgensen iD

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad076 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Sarah C J Jorgensen. Beteiligte Einrichtung: Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto M5S 1A8, Ontario, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a leading cause of hospitalization and infant mortality worldwide. There are currently no approved vaccines against RSV, and immunoprophylaxis with the mAb palivizumab is limited to extremely vulnerable infants in resource-rich settings due to its high cost and the need for monthly injections throughout the RSV season. Nirsevimab (formerly MEDI8897) is a highly potent, long-acting, human, recombinant mAb that received approval for the prevention of RSV infection in newborns and infants during their first RSV season from the EMA and the UK’s Medicines and Healthcare products Regulatory Agency in November 2022 based on positive results in Phase 2b and 3 clinical trials. Nirsevimab targets the highly conserved site Ø of the prefusion conformation of the RSV fusion (F) protein and contains a triple amino acid substitution in the Fc domain that extends its half-life, allowing for a single dose to cover a typical RSV season in regions with temperate climates. In this article I review key attributes of nirsevimab with an emphasis on pharmacology, pharmacokinetics, antiviral activity, and the potential for resistance and escape variants. I also summarize current progress in clinical trials and consider future research priorities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanHumansInfant, NewbornInfantAntiviral AgentsAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Substanzen

Antiviral AgentsnirsevimabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto M5S 1A8, Ontario, Canada.

ORCID-Profile: Sarah C J Jorgensen

Zitieren

APA

Jorgensen, S. C. J. (2023). Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad076

Vancouver

Jorgensen SCJ. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad076

BibTeX
@article{Jorgensen2023,
  author = {Jorgensen, Sarah C J},
  title = {Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad076}
}
Kostenlos starten →